

Date and Time: 17th May 2013 10:00–16:00

Minutes: Draft

Chronic kidney disease: Early identification and management of chronic kidney disease in adults in primary and secondary care (partial update)

Guideline Development Group Meeting 7

Place: NCGC, 180 Great Portland Street, London

Present: Paul Stephens (Chair) PS
Caroline Blaine (Research fellow) CB
Serena Carville (Senior research fellow / project manager) SC
Elisabetta Fenu (Senior health economist) EF
Lilian Li (Health economist) LL
Jill Parnham (Guideline lead) JP
Jacoby Patterson, Research Fellow (JPat)

Hugh Gallagher (Nephrologist) HG
Kathryn Griffith (GP) KG
Karen Jenkins (Renal nurse) KJ
Paul Kendrew (Renal pharmacist) PK
Ed Lamb (Clinical biochemist) EL
Robert Lewis (Nephrologist) RL
Fiona Loud (Lay member) FL
Nicholas Palmer (Lay member) NP
Paul Roderick (Professor of public health) PR
Shelagh O’Riordan (Geriatrician) SO

Apologies Quyen Chu (Senior Project Manager) QC
Paula D’Souza (Renal nurse) PD

In attendance Caroline Ashley, Renal Pharmacist, Royal Free London (until 1:30pm)
Daniel Lasserson, Senior Clinical Researcher, Department of Primary Healthcare Sciences, University of Oxford (until 1:30pm)

NICE staff	Ben Doak, (Guideline Commissioning Manager)	
------------	---	--

Notes

1. Introductions and apologies. PS welcomed everyone to the meeting. Apologies were noted from Quyen and Paula.

Caroline Ashley and Daniel Lasserson were introduced as invited experts attending the meeting to inform the discussions of the renin-angiotensin-aldosterone system antagonists review in place of GDG members who have conflicts of interest precluding them from participating in these discussions.
2. Declarations of Interest. All GDG members were asked to verbally declare any new declarations of interests since GDG6. Paul Kendrew declared that he is awaiting payment for a talk at the Pharmacy Congress in April (details of the conference here <http://www.pharmacycongress.co.uk/the-conference>), and awaiting payment for a talk for the centre for postgraduate pharmacy education (CPPE) on chronic kidney disease in May. Actions were agreed as declare and participate.

No other GDG members had any new declarations for today's meeting. The two invited experts also had no conflicts to declare.

Due to previously declared conflicts of interest, Kathryn Griffith, Karen Jenkins and Paul Kendrew were only attending for the afternoon session of today's meeting after all discussions of the renin-angiotensin-aldosterone system antagonists review had been completed.
3. Draft working notes and NICE minutes from GDG6. The draft working notes from GDG6 were agreed with a few minor corrections and the NICE minutes from GDG6 were agreed as an accurate reflection of the meeting and signed-off.
4. Evidence review: Renin-angiotensin-aldosterone system antagonists. The clinical evidence was presented by SC and the economic evidence was presented by LL. The GDG discussed draft recommendations.
5. Health economic Cystatin C cost analysis. LL presented the updated economic analysis. The GDG discussed the presentation and content, and suggested some amendments to the inputs.
6. Draft recommendations. The GDG reviewed the draft recommendations made to date and some amendments were made.
7. Any other business. Key time points for guideline milestones were presented to the GDG.

Date, time and venue of the next meeting

GDG8: 21st June, 10–4pm, Boardroom, NCGC offices, 180 Great Portland Street